Eye Infections Treatment Market Outlook (2022-2030)

[256 Pages Report] Worldwide revenue from the global Eye Infections Treatment Market is estimated at US$ 7.3 Billion for 2022, and the market is projected to progress at a CAGR of 3.8% from 2022 to 2030. Demand for eye infections treatment is anticipated to reach a worth of US$ 9.9 Billion by the end of 2030.

Attributes Details
Eye Infections Treatment Market Size (2022) US$ 7.3 Billion
Predicted Revenue (2030) US$ 9.9 Billion
Forecasted Growth Rate (2022 to 2030) 3.8% CAGR
Dominant Dosage Form Eye Drops - 60.2%

Eye infections treatment products account for 17.2% share of the global antibiotic market at present. OTC eye infection drops are expected to have a bright outlook over the decade.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

How The Market Progressed Till June 2022?

Particulars Details
H1, 2021 3.79%
H1, 2022 Projected 3.84%
H1, 2022 Outlook 3.74%
BPS Change - H1, 2022 (O) - H1, 2022 (P) (-) 10 ↓
BPS Change - H1, 2022 (O) - H1, 2021 (-) 05 ↓

As per the FMI analysis, the H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 10 BPS. In H1-2022 when compared with H1-2021, the market growth rate of eye infections treatment is expected to fall by only 05 basis point share (BPS), as per FMI analysis.

The decline in the BPS values observed was attributed to the decrease in the cases of outpatient eye consultations, disruption in supply chain and distribution of ophthalmic eye drops, and the growing cases of infectious disease proliferation which was untended to during the lockdown period of the COVID-19 pandemic.

Conversely, rising pharmaceuticals production facilities in several economies such as India will splurge the growth output scenario of the overall market during the forecast period.

Key developments in the market include the development of intravitreal antibiotics. The market is highly influenced by regulatory impositions, disease epidemiology, and patient compliance, under the impact of macro and industry factors.

Analysis Of Eye Infections Treatment Industry (2015 To 2021) Vs Market Predictions (2022 To 2030)

Eye infections have seen a substantial rise in incidence over the past years and this has led to an increase in eye infections treatment demand, and this trend is expected to be prevalent over the coming years as well. The global eye disease treatment market rose at a CAGR of 3.7% from 2015 to 2021.

Increasing instances of glaucoma, cataracts, diabetic retinopathy, and age-related macular degeneration (AMD) have resulted in high demand for eye infections treatment. Rising geriatric population is one of the major factors driving the eye infections treatment industry potential.

Increasing sedentary lifestyle trends, emergence of new allergies, rising adoption of contact lenses, rising need for pink eye treatment, and increasing rate of eye surgeries are some other factors that are driving demand for the treatment of eye infections.

Demand for eye infections treatment is anticipated to progress at a steady 3.8% CAGR from 2022 to 2030.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What Factors Are Positively Influencing Eye Infections Treatment Market Potential?

“Market Driven by Rising Incidence of Multiple Vision Conditions across the World”

Instances of eye infections are expected to see a rise on a global level, and this is expected to propel demand for medicines for eye infections. Eye drops for conjunctivitis, pink eye drops, stye eye drops, and keratitis eye drops are some prominent treatment options that are expected to see high demand over the forecast period. Eye infections treatment providers are launching new products to increase their market presence and boost revenues across the world.

  • For instance, NovaBay Pharmaceuticals, in January 2022, announced the launch of new eye drops that are designed to treat dry eye symptoms. This is a new over-the-counter medicine for dry eyes, which is a condition that has seen an increase in incidence over the past years.

“Technical Advancements in Diagnosis & Treatment for Eye Infections to Fuel Market Potential”

Constant research & development are evident in the healthcare industry and this is common for eye disease treatment and diagnosis as well. Post-operative ocular infections have been a major cause of concern as they account for a significant amount of total eye infections in the world.

Eye infections treatment providers are investing in the research and development of new diagnostic and treatment procedures to minimize the risks of infections in ocular surgeries. Increasing technological advancements are expected to influence the eye infections treatment market over the coming years.

  • For instance, TearClear, an ophthalmic pharmaceutical firm, announced the initiation of phase 3 of its trial for a preservative-free ophthalmic solution. Evaluation of TC-002 in patients with glaucoma is the main focus of this trial, and this phase brings it one step closer to market launch.

How Is The Eye Infections Treatment Market Expected To Perform Across Regions?

“Emerging Economies of India and China to Provide Lucrative Opportunities”

The global eye infections treatment industry survey provides detailed analysis of the market across regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).

The eye infections treatment market in North America is expected to have a bright outlook over the forecast period, and most of the growth in this region is anticipated to be driven by the easy availability of eye treatments and high adoption of eye lenses.

The market for eye infections treatment in Europe is anticipated to be majorly governed by the increasing geriatric population in the region. Rising focus on healthcare infrastructure is also expected to crucially influence market potential over the coming years.

The market for eye infections treatment in regions such as East Asia and South Asia is anticipated to see significant demand from emerging economies such as India and China. High population density in these regions and developing healthcare infrastructure provide a lucrative setting for eye infections treatment product manufacturers.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-Wise Analysis

Why the U.S. is a Highly Lucrative Market for Eye Infections Treatment Vendors?

“U.S. Market Driven by High Incidence of Eye Infections and Increasing Need for Eye Surgeries”

Advanced healthcare infrastructure provides a lucrative setting for eye infection treatments in the U.S. Increasing number of eye surgeries, rising usage of eye lenses, rising geriatric population, etc. are some factors that propel demand in the U.S.

  • Laboratoires Théa SAS, in January 2022, announced an agreement with Akorn Operating Company LLC to strengthen its presence in the U.S. eye care market. Via this agreement, Théa will be purchasing seven ophthalmic products from Akorn to fulfil the needs of eye care professionals in the U.S.

Is India a Beneficial Market for Eye Infections Treatment Providers?

“Eye Infections Treatment Companies to Benefit from Developing Healthcare Infrastructure in India”

India has seen a substantial increase in focus on eye infections treatment as instances of eye diseases in the nation has risen. Developing healthcare infrastructure provides eye infections treatment equipment suppliers an opportunity to discover the untapped market potential in India.

Increasing geriatric population, rising availability of eye infection medicines, increasing popularity of OTC eye drops, rising awareness about eye infections, etc. are major factors governing the eye infections treatment industry in India.

Category-Wise Analysis

Why is Demand for Eye Drops for Infection Treatment the Highest?

“Antibiotic Eye Drops to See Hike in Demand through 2030”

Eye drops have proven their effectiveness in the treatment of various eye diseases and eye infections and are a preferred treatment choice among patients as well. Stye eye drops, antiviral eye drops, antibiotic eye drops, pink eye drops, eye drops for conjunctivitis, and eye drops for blepharitis are some of the most used eye drops in the eye treatment industry.

OTC eye infection drops are expected to see an increase in demand. With a rise in instances of stye eye, pink eye, conjunctivitis, etc., demand for eye drops is expected to be a prominent trend over the forecast period as well.

Currently, the eye drops segment accounts for a mammoth share of 60.2% in the global eye infections treatment devices market, and is anticipated to maintain its dominance through 2030.

COVID-19 Pandemic Impact

In 2020, as the pandemic hit the world all resources were directed to fend off infections and contain coronavirus in the most effective way possible. This adversely affected the eye infections treatment marketplace and other health conditions saw a decrease in diagnostic availability.

However, as the pandemic subsides and the world returns to a new normal, we are expecting eye infections treatment to make a steady recovery. Delayed diagnostic opportunities and increased focus on healthcare are expected to be prominent trends in the post-pandemic era and influence eye infections treatment demand.

Competitive Landscape

Eye infections treatment product suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales. Approval for new medications and treatments for eye infections is also expected to be a major trend over the coming years.

  • In December 2021, Vuity, a new eye drop medicine was launched for presbyopia which affects millions of people across the world. It was approved by FDA in October and provides a sharper vision for 6 – 10 hours and starts showing effect in 15 minutes of application.

Eye Infections Treatment Industry Report Scope

Attribute Details
Forecast Period 2022 to 2030
Historical Data Available for 2015 to 2021
Market Analysis US$ Million for Value
Key Regions Covered
  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa (MEA)
Key Countries Covered
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • Turkey
  • South Africa
  • and GCC Countries
Key Market Segments Covered
  • Drug Class
  • Dosage Form
  • Indication
  • Causative Agent
  • Distribution Channels
  • Region
Key Companies Profiled
  • Allergan plc
  • Alcon Laboratories Inc.
  • Bausch Health Companies Inc.
  • Pfizer Inc.
  • Akron Pharma Inc
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Intas Pharmaceuticals Ltd
  • Johnson & Johnson Services Inc.
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co. Inc.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
Pricing Available upon Request

Key Segments Of Eye Infections Treatment Industry Survey

By Drug Class:

  • Antibiotics
    • Sulfonamides
    • Macrolides
    • Erythromycin
    • Chloramphenicol
    • Aminoglycosides
    • Fluoroquinolones
    • Vancomycin
    • Tetracyclines
  • Antivirals
    • Thymidine-Based Nucleoside Analogues (Trifluridine)
    • Thymidine Phosphorylase Inhibitors (Trifluridine)
    • Acyclic Nucleoside Analogue of 2'Deoxyguanasine (Ganciclovir)
    • Acyclic Guanine Nucleoside Analog (Acyclovir)
    • Others
  • Antifungals
    • Polyenes (Amphotericin B (AMB) And Natamycin (NTM))
    • Azoles (Miconazole (MCZ), Econazole (ECZ) And Ketoconazole (KCZ))
    • Pyrimidines
    • Echinocandins (Caspofungin (CFG) and Micafungin (MFG))
    • Others
  • Antihistamines
  • Corticosteroids
  • Glucocorticoids

By Dosage Form:

  • Eye Infections Treatment Tablets
  • Eye Infections Treatment Capsules
  • Eye Infections Treatment Ophthalmic Ointments
  • Eye Infections Treatment Eye Drops
  • Others

By Indication:

  • Eye Infections Treatment for Conjunctivitis
  • Eye Infections Treatment for Keratitis
  • Eye Infections Treatment for Endophthalmitis
  • Eye Infections Treatment for Blepharitis
  • Eye Infections Treatment for Stye or Sty (Hordeolum)
  • Eye Infections Treatment for Uveitis
  • Eye Infections Treatment for Cellulitis
  • Eye Infections Treatment for Ocular Herpes

By Causative Agent:

  • Virus
  • Bacteria
  • Fungus
  • Allergens

By Distribution Channels:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

By Region:

  • North America Eye Infections Treatment Market
  • Latin America Eye Infections Treatment Market
  • Europe Eye Infections Treatment Market
  • East Asia Eye Infections Treatment Market
  • South Asia & Pacific Eye Infections Treatment Market
  • Middle East & Africa (MEA) Eye Infections Treatment Market

Frequently Asked Questions

How is demand for eye infections treatment predicted to rise over the forecast period?

The global eye infections treatment market is projected to exhibit a CAGR of 3.8% from 2022 to 2030.

What market share is held by eye drops in 2022?

At present, eye drops account for a dominant market share of 60.2% in the global eye infections treatment industry.

Who are the prime players profiled in this eye infections treatment market survey?

Prime eye infections treatment product manufacturers are Allergan plc, Alcon Laboratories Inc., Bausch Health Companies Inc., Pfizer Inc., Akron Pharma Inc., Sanofi S.A., and GlaxoSmithKline plc.

How big is the eye infections treatment market at present?

Currently, the global eye infections treatment market is worth US$ 7.3 Bn.

What is the projected net worth for the year 2030?

The eye infections treatment market is predicted to reach an estimated valuation of US$ 9.9 Bn by 2030.

Table of Content

1. Executive Summary

     1.1. Global Market Outlook

     1.2. Demand Side Trends

     1.3. Supply Side Trends

     1.4. Technology Roadmap

     1.5. Analysis and Recommendations

2. Market Overview

     2.1. Market Coverage / Taxonomy

     2.2. Market Definition / Scope / Limitations

     2.3. Inclusions and Exclusions

3. Key Market Trends

     3.1. Key Trends Impacting the Market

     3.2. Development Trends

4. Market Background

     4.1. Macro-Economic Factors

          4.1.1. Global GDP Growth Outlook

          4.1.2. Global Healthcare Spending Outlook

     4.2. Forecast Factors - Relevance & Impact

          4.2.1. Adoption of Drugs

          4.2.2. Disease Prevalence

          4.2.3. Reimbursement scenario

          4.2.4. Regulatory Scenario

          4.2.5. Product in Pipeline

     4.3. Market Dynamics

          4.3.1. Drivers

          4.3.2. Restraints

          4.3.3. Opportunity Analysis

5. Market Context

     5.1. Drug Type vs Indication Analysis

     5.2. Strategic Promotional Analysis, By Key Manufacturers

     5.3. Key Regulations

     5.4. Porter’s Five Forces Analysis

     5.5. PESTLE Analysis

6. COVID19 Crisis Analysis 

     6.1. Current COVID19 Statistics and Probable Future Impact

     6.2. Current GDP Projection and Probable Impact

     6.3. Current Economic Projection as compared to 2008 financial analysis

     6.4. COVID19 and Impact Analysis

          6.4.1. Revenue By Product

          6.4.2. Revenue By Dosage Form

          6.4.3. Revenue By Country

     6.5. 2022 Market Scenario

     6.6. Quarter by Quarter Forecast

     6.7. Projected recovery Quarter

     6.8. Recovery Scenario - Short term, Midterm and Long Term Impact Global

7. Global Eye Infection treatment Market Demand (in Value or Size in US$ Mn) Analysis 2015-2021 and Forecast, 2022-2030

     7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021

     7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2030

          7.2.1. Y-o-Y Growth Trend Analysis

8. Global Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Drug Class 

     8.1. Introduction / Key Findings

     8.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2015 - 2021

     8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2022 - 2030

          8.3.1. Antibiotics 

                8.3.1.1. Sulfonamides

                8.3.1.2. Macrolides

                8.3.1.3. Erythromycin

                8.3.1.4. Chloramphenicol

                8.3.1.5. Aminoglycosides

                8.3.1.6. Fluoroquinolones

                8.3.1.7. Vancomycin

                8.3.1.8. Tetracyclines

          8.3.2. Antivirals

                8.3.2.1. Thymidine-Based Nucleoside Analogues (Trifluridine)

                8.3.2.2. Thymidine Phosphorylase Inhibitors (Trifluridine)

                8.3.2.3. Acyclic Nucleoside Analogue of 2'Deoxyguanasine (Ganciclovir)

                8.3.2.4. Acyclic Guanine Nucleoside Analog (Acyclovir)

                8.3.2.5. Others

          8.3.3. Antifungals

                8.3.3.1. Polyenes (Amphotericin B (AMB) And Natamycin (NTM))

                8.3.3.2. Azoles (Miconazole (MCZ), Econazole (ECZ) And Ketoconazole (KCZ))

                8.3.3.3. Pyrimidines

                8.3.3.4. Echinocandins (Caspofungin (CFG) and Micafungin (MFG))

                8.3.3.5. Others

          8.3.4. Antihistamines

          8.3.5. Corticosteroids

          8.3.6. Glucocorticoids 

     8.4. Market Attractiveness Analysis By Drug Class

9. Global Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Dosage Form 

     9.1. Introduction / Key Findings

     9.2. Historical Market Size (US$ Mn) Analysis By Dosage Form, 2015 - 2021

     9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Dosage Form, 2022 - 2030

          9.3.1. Tablet

          9.3.2. Capsule 

          9.3.3. Ophthalmic Ointment

          9.3.4. Eye Drops 

          9.3.5. Others 

     9.4. Market Attractiveness Analysis By Dosage Form

10. Global Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Indication 

     10.1.Introduction / Key Findings

     10.2.Historical Market Size (US$ Mn) Analysis By Indication, 2015 - 2021

     10.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022 - 2030

          10.3.1. Conjunctivitis

          10.3.2. Keratitis

          10.3.3. Endophthalmitis

          10.3.4. Blepharitis

          10.3.5. Stye or Sty (Hordeolum)

          10.3.6. Uveitis

          10.3.7. Cellulitis

          10.3.8. Ocular herpes 

     10.4.Market Attractiveness Analysis By Indication

11. Global Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Causative Agent

     11.1.Introduction / Key Findings

     11.2.Historical Market Size (US$ Mn) Analysis By Causative Agent, 2015 - 2021

     11.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Causative Agent, 2022 - 2030

          11.3.1. Virus

          11.3.2. Bacteria

          11.3.3. Fungus

          11.3.4. Allergens

     11.4.Market Attractiveness Analysis By Causative Agent

12. Global Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Distribution Channel

     12.1.Introduction / Key Findings

     12.2.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015 - 2021

     12.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022 - 2030

          12.3.1. Hospital Pharmacy

          12.3.2. Retail Pharmacy

          12.3.3. Drug Stores

          12.3.4. Online Pharmacy

     12.4.Market Attractiveness Analysis By Distribution Channel

13. Global Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Region

     13.1.Introduction

     13.2.Historical Market Size (US$ Mn) Analysis By Region, 2015 - 2021

     13.3.Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022 - 2030

          13.3.1. North America

          13.3.2. Latin America

          13.3.3. Europe

          13.3.4. South Asia

          13.3.5. East Asia

          13.3.6. Oceania

          13.3.7. Middle East and Africa (MEA)

     13.4.Market Attractiveness Analysis By Region

14. North America Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030

     14.1. Introduction

     14.2. Pricing Analysis

     14.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2021

     14.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022 - 2030

          14.4.1. By Country

                14.4.1.1. U.S.

                14.4.1.2. Canada

          14.4.2. By Drug Class

          14.4.3. By Dosage Form

          14.4.4. By Indications

          14.4.5. By Causative Agent

          14.4.6. By Distribution Channel

     14.5. Market Attractiveness Analysis

          14.5.1. By Country

          14.5.2. By Drug Class

          14.5.3. By Dosage Form

          14.5.4. By Indications

          14.5.5. By Causative Agent

          14.5.6. By Distribution Channel

     14.6. Market Trends

     14.7. Key Market Participants - Intensity Mapping

     14.8. Drivers and Restraints - Impact Analysis

15. Latin America Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030

     15.1. Introduction

     15.2. Pricing Analysis

     15.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2021

     15.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022 - 2030

          15.4.1.  By Country

                15.4.1.1. Brazil

                15.4.1.2. Mexico

                15.4.1.3. Rest of Latin America

          15.4.2. By Drug Class

          15.4.3. By Dosage Form

          15.4.4. By Indications

          15.4.5. By Causative Agent

          15.4.6. By Distribution Channel

     15.5. Market Attractiveness Analysis

          15.5.1. By Country

          15.5.2. By Drug Class

          15.5.3. By Dosage Form

          15.5.4. By Indications

          15.5.5. By Causative Agent

          15.5.6. By Distribution Channel

     15.6. Market Trends

     15.7. Key Market Participants - Intensity Mapping

     15.8. Drivers and Restraints - Impact Analysis

16. Europe Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030

     16.1. Introduction

     16.2. Pricing Analysis

     16.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2021

     16.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2030

          16.4.1.  By Country

                16.4.1.1. Germany

                16.4.1.2. U.K.

                16.4.1.3. France

                16.4.1.4. France

                16.4.1.5. Italy

                16.4.1.6. Spain

                16.4.1.7. Russia

                16.4.1.8. Rest of Europe

          16.4.2. By Drug Class

          16.4.3. By Dosage Form

          16.4.4. By Indications

          16.4.5. By Causative Agent

          16.4.6. By Distribution Channel

     16.5. Market Attractiveness Analysis

          16.5.1. By Country

          16.5.2. By Drug Class

          16.5.3. By Dosage Form

          16.5.4. By Indications

          16.5.5. By Causative Agent

          16.5.6. By Distribution Channel

     16.6. Market Trends

     16.7. Key Market Participants - Intensity Mapping

     16.8. Drivers and Restraints - Impact Analysis

17. South Asia Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030

     17.1. Introduction

     17.2. Pricing Analysis

     17.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015 - 2021

     17.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2030

          17.4.1.  By Country

                17.4.1.1. India

                17.4.1.2. Thailand

                17.4.1.3. Indonesia

                17.4.1.4. Malaysia

                17.4.1.5. Rest of South Asia

          17.4.2. By Drug Class

          17.4.3. By Dosage Form

          17.4.4. By Indications

          17.4.5. By Causative Agent

          17.4.6. By Distribution Channel

     17.5.Market Attractiveness Analysis

          17.5.1. By Country

          17.5.2. By Drug Class

          17.5.3. By Dosage Form

          17.5.4. By Indications

          17.5.5. By Causative Agent

          17.5.6. By Distribution Channel

     17.6.Market Trends

     17.7.Key Market Participants - Intensity Mapping

     17.8.Drivers and Restraints - Impact Analysis

18. East Asia Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030

     18.1. Introduction

     18.2. Pricing Analysis

     18.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015 - 2021

     18.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2030

          18.4.1.  By Country

                18.4.1.1. China

                18.4.1.2. Japan

                18.4.1.3. South Korea

          18.4.2. By Drug Class

          18.4.3. By Dosage Form

          18.4.4. By Indications

          18.4.5. By Causative Agent

          18.4.6. By Distribution Channel

     18.5.Market Attractiveness Analysis

          18.5.1. By Country

          18.5.2. By Drug Class

          18.5.3. By Dosage Form

          18.5.4. By Indications

          18.5.5. By Causative Agent

          18.5.6. By Distribution Channel

     18.6 .Market Trends

     18.7. Key Market Participants - Intensity Mapping

     18.8. Drivers and Restraints - Impact Analysis

19. Oceania Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030

     19.1.Introduction

     19.2.Pricing Analysis

     19.3.Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2021

     19.4.Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2030

          19.4.1.  By Country

                19.4.1.1. Australia

                19.4.1.2. New Zealand

          19.4.2. By Drug Class

          19.4.3. By Dosage Form

          19.4.4. By Indications

          19.4.5. By Causative Agent

          19.4.6. By Distribution Channel

     19.5.Market Attractiveness Analysis

          19.5.1. By Country

          19.5.2. By Drug Class

          19.5.3. By Dosage Form

          19.5.4. By Indications

          19.5.5. By Causative Agent

          19.5.6. By Distribution Channel

     19.6.Market Trends

     19.7.Key Market Participants - Intensity Mapping

     19.8.Drivers and Restraints - Impact Analysis

20. Middle East and Africa Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030

     20.1.Introduction

     20.2.Pricing Analysis

     20.3.Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2021

     20.4.Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2030

          20.4.1.  By Country

                20.4.1.1. GCC Countries

                20.4.1.2. Turkey

                20.4.1.3. Northern Africa

                20.4.1.4. South Africa

                20.4.1.5. Rest of Middle East and Africa

          20.4.2. By Drug Class

          20.4.3. By Dosage Form

          20.4.4. By Indications

          20.4.5. By Causative Agent

          20.4.6. By Distribution Channel

     20.5.Market Attractiveness Analysis

          20.5.1. By Country

          20.5.2. By Drug Class

          20.5.3. By Dosage Form

          20.5.4. By Indications

          20.5.5. By Causative Agent

          20.5.6. By Distribution Channel

     20.6.Market Trends

     20.7.Key Market Participants - Intensity Mapping

     20.8.Drivers and Restraints - Impact Analysis

21. Emerging Countries Eye Infection treatment Market Analysis 2015-2021 and Forecast 2022-2030

     21.1.Introduction

          21.1.1. Market Value Proportion Analysis, By Key Countries

          21.1.2. Global Vs. Country Growth Comparison

     21.2.China Eye Infection treatment Market Analysis

          21.2.1. Introduction

          21.2.2. Pricing Analysis

          21.2.3. PEST Analysis

          21.2.4. Market Value Proportion Analysis by Market Taxonomy

          21.2.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy

                21.2.5.1. By Drug Class

                21.2.5.2. By Dosage Form

                21.2.5.3. By Indications

                21.2.5.4. By Causative Agent

                21.2.5.5. By Distribution Channel

          21.2.6. China Eye Infection treatment Market - Competition Landscape

          21.2.7. China - Trade Analysis

     21.3.India Eye Infection treatment Market Analysis

          21.3.1. Introduction

          21.3.2. Pricing Analysis

          21.3.3. PEST Analysis

          21.3.4. Market Value Proportion Analysis by Market Taxonomy

          21.3.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy

                21.3.5.1. By Drug Class

                21.3.5.2. By Dosage Form

                21.3.5.3. By Indications

                21.3.5.4. By Causative Agent

                21.3.5.5. By Distribution Channel

          21.3.6. India Eye Infection treatment Market - Competition Landscape

     21.4.Brazil Eye Infection treatment Market Analysis

          21.4.1. Introduction

          21.4.2. Pricing Analysis

          21.4.3. PEST Analysis

          21.4.4. Market Value Proportion Analysis by Market Taxonomy

          21.4.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy

                21.4.5.1. By Drug Class

                21.4.5.2. By Dosage Form

                21.4.5.3. By Indications

                21.4.5.4. By Causative Agent

                21.4.5.5. By Distribution Channel

          21.4.6. Brazil Eye Infection treatment Market - Competition Landscape

22. Market Structure Analysis

     22.1.Market Analysis by Tier of Companies (Eye Infection treatment)

     22.2.Market Concentration

     22.3.Market Share Analysis of Top Players

     22.4.Market Presence Analysis

          22.4.1. By Regional footprint of Players

          22.4.2. Product foot print by Players

          22.4.3. Channel Foot Print by Players

23. Competition Analysis

     23.1.Competition Dashboard

     23.2.Pricing Analysis by Competition

     23.3.Competition Benchmarking

     23.4.Competition Deep Dive

          23.4.1. Allergan plc

                23.4.1.1. Overview

                23.4.1.2. Product Portfolio

                23.4.1.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.1.4. Sales Footprint

                23.4.1.5. Strategy Overview

                      23.4.1.5.1. Marketing Strategy

                      23.4.1.5.2. Product Strategy

                      23.4.1.5.3. Channel Strategy

          23.4.2. Alcon Laboratories, Inc.

                23.4.2.1. Overview

                23.4.2.2. Product Portfolio

                23.4.2.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.2.4. Sales Footprint

                23.4.2.5. Strategy Overview

                      23.4.2.5.1. Marketing Strategy

                      23.4.2.5.2. Product Strategy

                      23.4.2.5.3. Channel Strategy

          23.4.3. Bausch Health Companies Inc.

                23.4.3.1. Overview

                23.4.3.2. Product Portfolio

                23.4.3.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.3.4. Sales Footprint

                23.4.3.5. Strategy Overview

                      23.4.3.5.1. Marketing Strategy

                      23.4.3.5.2. Product Strategy

                      23.4.3.5.3. Channel Strategy

          23.4.4. Pfizer Inc.

                23.4.4.1. Overview

                23.4.4.2. Product Portfolio

                23.4.4.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.4.4. Sales Footprint

                23.4.4.5. Strategy Overview

                      23.4.4.5.1. Marketing Strategy

                      23.4.4.5.2. Product Strategy

                      23.4.4.5.3. Channel Strategy

          23.4.5. Akron Pharma Inc.

                23.4.5.1. Overview

                23.4.5.2. Product Portfolio

                23.4.5.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.5.4. Sales Footprint

                23.4.5.5. Strategy Overview

                      23.4.5.5.1. Marketing Strategy

                      23.4.5.5.2. Product Strategy

                      23.4.5.5.3. Channel Strategy

          23.4.6. Sanofi S.A.

                23.4.6.1. Overview

                23.4.6.2. Product Portfolio

                23.4.6.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.6.4. Sales Footprint

                23.4.6.5. Strategy Overview

                      23.4.6.5.1. Marketing Strategy

                      23.4.6.5.2. Product Strategy

                      23.4.6.5.3. Channel Strategy

          23.4.7. GlaxoSmithKline plc

                23.4.7.1. Overview

                23.4.7.2. Product Portfolio

                23.4.7.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.7.4. Sales Footprint

                23.4.7.5. Strategy Overview

                      23.4.7.5.1. Marketing Strategy

                      23.4.7.5.2. Product Strategy

                      23.4.7.5.3. Channel Strategy

          23.4.8. Intas Pharmaceuticals Ltd

                23.4.8.1. Overview

                23.4.8.2. Product Portfolio

                23.4.8.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.8.4. Sales Footprint

                23.4.8.5. Strategy Overview

                      23.4.8.5.1. Marketing Strategy

                      23.4.8.5.2. Product Strategy

                      23.4.8.5.3. Channel Strategy

          23.4.9. Johnson & Johnson Services, Inc.

                23.4.9.1. Overview

                23.4.9.2. Product Portfolio

                23.4.9.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.9.4. Sales Footprint

                23.4.9.5. Strategy Overview

                      23.4.9.5.1. Marketing Strategy

                      23.4.9.5.2. Product Strategy

                      23.4.9.5.3. Channel Strategy

          23.4.10. Macleods Pharmaceuticals Ltd.

                23.4.10.1. Overview

                23.4.10.2. Product Portfolio

                23.4.10.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.10.4. Sales Footprint

                23.4.10.5. Strategy Overview

                      23.4.10.5.1. Marketing Strategy

                      23.4.10.5.2. Product Strategy

                      23.4.10.5.3. Channel Strategy

          23.4.11. Merck & Co., Inc.

                23.4.11.1. Overview

                23.4.11.2. Product Portfolio

                23.4.11.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.11.4. Sales Footprint

                23.4.11.5. Strategy Overview

                      23.4.11.5.1. Marketing Strategy

                      23.4.11.5.2. Product Strategy

                      23.4.11.5.3. Channel Strategy

          23.4.12. Mylan N.V.

                23.4.12.1. Overview

                23.4.12.2. Product Portfolio

                23.4.12.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.12.4. Sales Footprint

                23.4.12.5. Strategy Overview

                      23.4.12.5.1. Marketing Strategy

                      23.4.12.5.2. Product Strategy

                      23.4.12.5.3. Channel Strategy

          23.4.13. Teva Pharmaceutical Industries Ltd.

                23.4.13.1. Overview

                23.4.13.2. Product Portfolio

                23.4.13.3. Profitability by Market Segments (Product/Channel/Region)

                23.4.13.4. Sales Footprint

                23.4.13.5. Strategy Overview

                      23.4.13.5.1. Marketing Strategy

                      23.4.13.5.2. Product Strategy

                      23.4.13.5.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology

Recommendations

Healthcare

Corneal Ulcer Treatment Market

December 2024

REP-GB-6953

429 pages

Healthcare

Infection Prevention Market

December 2023

REP-GB-13950

333 pages

Healthcare

Vision Care Market

August 2023

REP-GB-822

342 pages

Healthcare

Swab and Viral Transport Medium Market

March 2023

REP-GB-11195

333 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Eye Infections Treatment Market

Schedule a Call